<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01577316</url>
  </required_header>
  <id_info>
    <org_study_id>CI 1059_1170</org_study_id>
    <nct_id>NCT01577316</nct_id>
  </id_info>
  <brief_title>Evaluate the Immunogenicity and Safety of the 2011-2012 Vaccine Against Seasonal Influenza on Pregnant Women</brief_title>
  <acronym>VACINFL2011</acronym>
  <official_title>Clinical Trial to Evaluate the Immunogenicity and Safety of the 2011-2012 Vaccine Against Seasonal Influenza on Pregnant Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Nacional de Salud Publica, Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Laboratorios de Biologicos y Reactivos de México, S.A. de C.V.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto Nacional de Salud Publica, Mexico</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis proposed in this study is that the 2011-2012 Seasonal Influenza Vaccine&#xD;
      (including H3N2 and H1N1 subtypes of serotype A strain over the serotype B) administered to&#xD;
      15ug (without adjuvant) via intramuscular in pregnant women will be safe and immunogenic.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite the fact that influenza vaccination of pregnant women is amply recommended, coverage&#xD;
      of influenza vaccination is low. In general, there are few studies on safety of the vaccine&#xD;
      to this group, particularly during the first three months of pregnancy or evaluating&#xD;
      trivalent vaccines containing inactivated pandemic 2009 H1N1 virus. Studies are controversial&#xD;
      regarding passage of maternal antibodies and protection to the newborn. The investigators&#xD;
      propose to evaluate safety and immunogenicity of 2011-2012 seasonal trivalent influenza&#xD;
      vaccine (Northern hemisphere)(containing an A/California/7/2009 (H1N1)-like virus; an&#xD;
      A/Perth/16/2009 (H3N2)-like virus; a B/Brisbane/60/2008-like virus) produced by Sanofi&#xD;
      Pasteur. Study design is a Phase II/III, two arm, non-randomized clinical trial. The&#xD;
      investigators will recruit 120 pregnant women, 18 to 39 years of age, 14 to 34 week pregnant&#xD;
      and 120 non-pregnant women. Trivalent influenza vaccine (0.5ml) will be administered IM in&#xD;
      the deltoid zone. Participants will be observed for 30 min post-vaccination for acute adverse&#xD;
      reactions and periodically during the 60 days post-vaccination for reactogenicity, adverse&#xD;
      effects and severe adverse effects. Baseline and 28 day influenza antibodies will be measured&#xD;
      by hemagglutination and microneutralization. Umbilical cord blood (10ml) will be drawn during&#xD;
      delivery. Newborns will be followed monthly for growth and morbidity up to six months of age.&#xD;
      If necessary, they will be referred for appropriate clinical care. Main outcome will be&#xD;
      seroconversion and seroresponse at 28 days post vaccination. Results will be adjusted by&#xD;
      study group and other relevant covariables.Safety will be analyzed according to type,&#xD;
      severity and study group.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>April 2012</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>Day 28</time_frame>
    <description>The results of this analysis will determine whether the vaccine provides protection based on the immunogenicity provided by the vaccine. They identify specific antibodies against influenza virus A (H1N1), will carry out the serological techniques by hemagglutination inhibition and microneutralization. The immunogenicity analysis will be measured by seroconversion and seroresponse</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>30 minutes immediate, day 1, 3, 5,7,11, 15 and 28</time_frame>
    <description>Monitoring of pregnant women will be at monthly intervals until the time of the birth.&#xD;
Pregnant women and nonpregnant are going to be monitored for 30 min after vaccination to monitor immediate clinical reactions, and at 28 days after completing a self-registration of possible events associated with vaccination, as well as follow-up home visits on days 1, 3, 5, 7, 11, 15, 21, and 28.&#xD;
At day 28, will be made a complete clinical evaluation and blood sampling for assessment of immunogenicity.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Pregnancy</condition>
  <condition>Investigation or Care in A Nonpregnant Woman</condition>
  <arm_group>
    <arm_group_label>Pregnant Woman</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pregnant Woman</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nonpregnant women</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2011-2012 Seasonal Influenza Vaccine (include A/California/7/2009 (H1N1)-like, A/Perth/16/2009 (H3N2)-like, and B/Brisbane/60/2008-like antigens) administered to 15ug without adjuvant, via intramuscular in pregnant and nonpregnant women.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Seasonal influenza vaccination</intervention_name>
    <description>2011-2012 Seasonal Trivalent Inactivated Influenza Vaccine (include A/California/7/2009 (H1N1)-like, A/Perth/16/2009 (H3N2)-like, and B/Brisbane/60/2008-like antigens) administered to 15ug without adjuvant, via intramuscular in pregnant and nonpregnant women.&#xD;
It is recommended that vaccines for use in the 2012-2013 influenza season (northern hemisphere winter) contain the following:&#xD;
an A/California/7/2009 (H1N1)pdm09-like virus;&#xD;
an A/Victoria/361/2011 (H3N2)-like virus;&#xD;
a B/Wisconsin/1/2010-like virus.</description>
    <arm_group_label>Nonpregnant women</arm_group_label>
    <arm_group_label>Pregnant Woman</arm_group_label>
    <other_name>Be recruited and will continue in parallel both groups</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        I.Selection Criteria in pregnant women&#xD;
&#xD;
        I.a.Inclusion Criteria&#xD;
&#xD;
          1. Pregnant women aged 18 to 39 years&#xD;
&#xD;
          2. Have made at least one prenatal visit to confirm the pregnancy&#xD;
&#xD;
          3. Available for follow-up time&#xD;
&#xD;
          4. To be from 14 to 34 weeks of gestation&#xD;
&#xD;
          5. If recruitment is conducted between August and November 2011, patient could have&#xD;
&#xD;
          6. Received the Seasonal Influence Vaccine from previous period, but not the H1N1 vaccine&#xD;
&#xD;
          7. Agree to participate in the study and provide informed consent&#xD;
&#xD;
          8. Good health according to the clinical evaluation of the participant, confirming: heart&#xD;
&#xD;
          9. Rate less than 100', systolic blood pressure less than 140 mm Hg, and diastolic less&#xD;
             or&#xD;
&#xD;
         10. Equal than 90 mmHg, and oral temperature less or equal than 37.4° C&#xD;
&#xD;
         11. Normal physical exam and laboratory test within 28 days prior to recruitment&#xD;
&#xD;
         12. HIV-negative test&#xD;
&#xD;
        I. b.Exclusion criteria&#xD;
&#xD;
          1. Preeclampsia or eclampsia&#xD;
&#xD;
          2. Treatment with immunosuppressive drugs&#xD;
&#xD;
          3. Receipt of blood products, 120 days prior to HIV screening&#xD;
&#xD;
          4. Receipt of immunoglobulin 60 days prior to screening for HIV&#xD;
&#xD;
          5. Have received live attenuated vaccines 30 days prior of vaccination&#xD;
&#xD;
          6. Have received inactivated vaccines within 14 days prior to vaccination&#xD;
&#xD;
          7. Treatment of latent or active tuberculosis&#xD;
&#xD;
          8. Autoimmune disease or immunodeficiency&#xD;
&#xD;
          9. Contraindication to receiving seasonal influenza vaccine&#xD;
&#xD;
         10. Vaccine side effects&#xD;
&#xD;
         11. History of angioedema.&#xD;
&#xD;
         12. Unstable asthma&#xD;
&#xD;
         13. Diabetes&#xD;
&#xD;
         14. Thyroidectomy or thyroid disease in the last 12 months&#xD;
&#xD;
         15. Idiopathic urticaria&#xD;
&#xD;
         16. Hypertension not well-controlled with treatment&#xD;
&#xD;
         17. Medically diagnosed bleeding diathesis, coagulopathy or platelet disorder&#xD;
&#xD;
         18. Active malignant tumor or in not-effective treatment&#xD;
&#xD;
         19. Asplenia&#xD;
&#xD;
         20. Allergic reaction to antibiotics&#xD;
&#xD;
         21. Guillain Barre&#xD;
&#xD;
         22. Psychiatric condition that difficult adherence to protocol&#xD;
&#xD;
        II.Selection criteria in nonpregnant woman&#xD;
&#xD;
        II. a.Inclusion criteria&#xD;
&#xD;
          -  Nonpregnant woman aged 18 to 39 years&#xD;
&#xD;
          -  Negative pregnancy test 24 hours prior to administration of the vaccine&#xD;
&#xD;
          -  Agree to participate in the study and provide informed consent&#xD;
&#xD;
          -  Good health according to the clinical evaluation of participant, confirming: heart&#xD;
             rate&#xD;
&#xD;
          -  less than 100 ', systolic blood pressure less than 140 mmHg, diastolic less than or&#xD;
             equal&#xD;
&#xD;
          -  to 90 mmHg, and oral temperature less than or equal to 37.4°C&#xD;
&#xD;
          -  Normal physical exam and laboratory test within 28 days prior to recruitment&#xD;
&#xD;
          -  HIV-negative test&#xD;
&#xD;
          -  Agree to not get pregnant during the study and follow an effective contraceptive&#xD;
&#xD;
          -  method&#xD;
&#xD;
          -  Good health, determined this by history&#xD;
&#xD;
          -  Receive the seasonal influenza vaccine at least two weeks prior to inclusion in this&#xD;
             study&#xD;
&#xD;
        II. b.Exclusion criteria&#xD;
&#xD;
          -  Being in treatment with immunosuppressive drugs&#xD;
&#xD;
          -  Receipt of blood products, 120 days prior to HIV screening&#xD;
&#xD;
          -  Receipt of immunoglobulin 60 days prior to screening for HIV&#xD;
&#xD;
          -  Have received live attenuated vaccines 30 days of vaccination&#xD;
&#xD;
          -  Have received inactivated vaccines within 14 days prior to vaccination&#xD;
&#xD;
          -  Treatment of latent or active tuberculosis&#xD;
&#xD;
          -  Autoimmune disease or immunodeficiency&#xD;
&#xD;
          -  Contraindication to receiving seasonal influenza vaccine&#xD;
&#xD;
          -  Vaccine side effects&#xD;
&#xD;
          -  History of angioedema&#xD;
&#xD;
          -  Unstable asthma&#xD;
&#xD;
          -  Diabetes Type 2&#xD;
&#xD;
          -  Thyroidectomy or thyroid disease requiring treatment in the past 12 months.&#xD;
&#xD;
          -  Idiopathic urticaria&#xD;
&#xD;
          -  Hypertension not well-controlled with treatment&#xD;
&#xD;
          -  Medically diagnosed bleeding diathesis, coagulopathy or platelet disorder&#xD;
&#xD;
          -  Active malignant tumor&#xD;
&#xD;
          -  Convulsive condition&#xD;
&#xD;
          -  Anatomic or functional asplenia&#xD;
&#xD;
          -  Allergic reaction to antibiotics&#xD;
&#xD;
          -  Guillain Barre&#xD;
&#xD;
          -  Psychiatric condition&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lourdes Garcia Garcia, DCs</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Nacional de Salud Publica, Mexico</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ferreyra-Reyes Leticia, MD</last_name>
    <phone>(52) 55 548710 00</phone>
    <phone_ext>4312</phone_ext>
    <email>freyes.ld@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Institute of Public Health</name>
      <address>
        <city>Cuernavaca</city>
        <state>Morelos</state>
        <zip>62100</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <contact>
      <last_name>Leticia Ferreyra-Reyes, MD</last_name>
      <phone>(52)5554871000</phone>
      <phone_ext>4312</phone_ext>
      <email>freyes.ld@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Renata Baez-Saldaña, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elizabeth Ferreira-Guerrero, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Leticia Ferreyra-Reyes, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guadalupe Delgado-Sánchez, MPH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luis Pablo Cruz-Hervert, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Samuel Ponce de Leon-Rosales, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Eugenia Jiménez-Corona, DSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <study_first_submitted>April 11, 2012</study_first_submitted>
  <study_first_submitted_qc>April 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2012</study_first_posted>
  <last_update_submitted>April 12, 2012</last_update_submitted>
  <last_update_submitted_qc>April 12, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 13, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Nacional de Salud Publica, Mexico</investigator_affiliation>
    <investigator_full_name>Ma. de Lourdes Garcia Garcia</investigator_full_name>
    <investigator_title>Director of the Center of Research in Infectious Diseases</investigator_title>
  </responsible_party>
  <keyword>vaccination</keyword>
  <keyword>Influenza</keyword>
  <keyword>Immunogenicity</keyword>
  <keyword>Safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

